A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.
Matthew A InghamShing M LeeBrian Andrew Van TineEdwin ChoyJay OzaSahil D DoshiLiner GePeter OppeltGregory M CoteBrian CorgiatNaomi SenderSarah Sta AnaLavan PanchalingamEmanuel F PetricoinGary K SchwartzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sitravatinib provided a PFR12 of 41% and meaningful disease control in a subset of patients with advanced, progressive WD/DD LPS.